May 25, 2023 10:24 AM EDT

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

Associate Editor

Senior Reporter

Sign up to read this article for free.

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data